A Randomised, Placebo-controlled, Double-blind, Multiple-dose, Dose-escalation Trial Investigating the Safety and Tolerability of NNC0114-0006 in Subjects With Systemic Lupus Erythematosus
Phase of Trial: Phase I
Latest Information Update: 17 Apr 2014
At a glance
- Drugs Anti-interleukin-21 monoclonal antibody (Primary)
- Indications Systemic lupus erythematosus
- Focus Adverse reactions
- Sponsors Novo Nordisk
- 07 Apr 2014 Status changed from completed to discontinued, as per ClinicalTrials.gov record.
- 18 Feb 2014 Status changed from active, no longer recruiting to completed, as per ClinicalTrials.gov record.
- 26 Nov 2013 Planned End Date changed from 1 Jan 2015 to 1 Feb 2014 as reported by ClinicalTrials.gov.